Biopharmaceutical News and Research

RSS

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

BioLineRx, a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040), a novel medical device intended for the prevention of cardiac remodeling following an acute myocardial infarction (AMI).

4 Jan 2012

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.

31 Dec 2011

Chengdu Tianyin receives approval for renewed High Tech Enterprise status

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today announced the approval of the Company's operating subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd's application for the renewal of its High Tech Enterprise Status in Chengdu, Sichuan Province of China.

30 Dec 2011

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Acceleron Pharma raises $30 million through private financing

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.

23 Dec 2011

UCF scientists pioneer new source of stem cell generation

A process that prompts a single gene to generate millions of supercharged stem cells, which can then turn into any kind of cell a body needs to repair itself, has been patented at the University of Central Florida.

23 Dec 2011

ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.

23 Dec 2011

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain.

19 Dec 2011

arGEN-X to advance SIMPLE Antibody platform for treatment of autoimmune disorders

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets.

19 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

Acurian, Onconova sign Clinical Trial Liaison Services agreement

Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, announced today that it has signed an agreement with Onconova Therapeutics, Inc., a private biopharmaceutical company located in Newtown, PA and Pennington, NJ.

13 Dec 2011

Quintiles launches Kun Tuo to service unique needs of biopharma companies in China

Further deepening its commitment to China, Quintiles today announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.

13 Dec 2011

Soligenix reports results from orBec Phase 2 trial on acute GVHD

Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

12 Dec 2011

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego.

12 Dec 2011

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.

9 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Heart patients may experience fewer traumas with new invention

Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.

8 Dec 2011

Janssen Biotech, Molecular Partners collaborate to develop DARPins for immunological diseases

Molecular Partners AG today announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin products for the treatment of immunological diseases.

8 Dec 2011

Roundup: Calif. to drop hospital report cards; Getting a doctor in N.Y. may depend on your neighborhood

The project was considered a pioneering effort when it started in 2004, but Jan Emerson-Shea, a spokesperson for the California Hospital Association, says the report cards have outlived their usefulness. "Today there are numerous places consumers can get information on the quality of care delivered by hospitals," Emerson-Shea says.

6 Dec 2011

Biogen, Samsung partner to develop and market biosimilars

Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

5 Dec 2011

Biopharmaceutical News and Research

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

Chengdu Tianyin receives approval for renewed High Tech Enterprise status

Alexion to acquire 100% of capital stock of Enobia

Acceleron Pharma raises $30 million through private financing

UCF scientists pioneer new source of stem cell generation

ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

arGEN-X to advance SIMPLE Antibody platform for treatment of autoimmune disorders

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Acurian, Onconova sign Clinical Trial Liaison Services agreement

Quintiles launches Kun Tuo to service unique needs of biopharma companies in China

Soligenix reports results from orBec Phase 2 trial on acute GVHD

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

Heart patients may experience fewer traumas with new invention

Janssen Biotech, Molecular Partners collaborate to develop DARPins for immunological diseases

Roundup: Calif. to drop hospital report cards; Getting a doctor in N.Y. may depend on your neighborhood

Biogen, Samsung partner to develop and market biosimilars

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News